New research presented at the European Respiratory Society (ERS) International Congress being held virtually until September 9, 2020, suggests “social smokers” are more than twice as likely to die of lung disease and over 8-times as likely to die of lung cancer vs non-smokers.
The study, titled “Association of low-intensity smoking with respiratory and lung cancer mortality,” also found that the risk of lung cancer mortality for “social smokers” (those who smoke <10 cigarettes/day) is not substantially lower vs heavy smokers (those who smoke ≥20 cigarettes/day).
The researchers – led by Pallavi Balte, PhD, and Elizabeth Oelsner, MD, MPH, both at Columbia University Medical Center in New York – noted that their study suggests that cutting down, or combining, fewer cigarettes with vaping, is not a substitute for quitting.
“Everyone knows that smoking is bad for you, but it’s easy to assume that if you only smoke a little, the risks won’t be too high,” said Balte to the virtual conference, according to an ERS press release. “Previous research suggests that people are cutting down on smoking, for example in the USA the proportion of smokers smoking less than ten cigarettes per day has increased from 16% to 27%. So, we wanted to study the risks to social smokers compared to people who don’t smoke and compared to heavier smokers.”
The study included 18 730 people selected from a multi-ethnic sample of the general US population; mean age was 61 years old, 56% women, 69% white, 13% current smokers. The median follow-up was 17 years, during which 649 participants died from respiratory causes and 560 died from lung cancer.
Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely.
Researchers calculated the death rates from respiratory disease and lung cancer and then compared these rates between non-smokers, social smokers, and heavy smokers. Researchers took account of other factors that can influence death rates including age, sex, race, education attainment, and body weight.
The results showed that social smokers were 2.5 times as likely to die of respiratory disease and 8.6 times as likely to die of lung cancer vs non-smokers. Social smokers had around half the rate of death from respiratory diseases as heavy smokers, however, their rate of lung cancer death was two-thirds that of heavy smokers.
“You might think that if you only smoke a few cigarettes a day you are avoiding most of the risk. But our findings [sis] suggesting that social smoking is disproportionately harmful. Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely,” added Balte.
“Social Smoking” Linked to Disproportionately High Risk of Death from Lung Disease, Lung Cancer
New research presented at the virtual European Respiratory Society International Congress showed "social smokers" are more than twice as likely to die of lung disease vs non-smokers.
New research presented at the European Respiratory Society (ERS) International Congress being held virtually until September 9, 2020, suggests “social smokers” are more than twice as likely to die of lung disease and over 8-times as likely to die of lung cancer vs non-smokers.
The study, titled “Association of low-intensity smoking with respiratory and lung cancer mortality,” also found that the risk of lung cancer mortality for “social smokers” (those who smoke <10 cigarettes/day) is not substantially lower vs heavy smokers (those who smoke ≥20 cigarettes/day).
The researchers – led by Pallavi Balte, PhD, and Elizabeth Oelsner, MD, MPH, both at Columbia University Medical Center in New York – noted that their study suggests that cutting down, or combining, fewer cigarettes with vaping, is not a substitute for quitting.
“Everyone knows that smoking is bad for you, but it’s easy to assume that if you only smoke a little, the risks won’t be too high,” said Balte to the virtual conference, according to an ERS press release. “Previous research suggests that people are cutting down on smoking, for example in the USA the proportion of smokers smoking less than ten cigarettes per day has increased from 16% to 27%. So, we wanted to study the risks to social smokers compared to people who don’t smoke and compared to heavier smokers.”
The study included 18 730 people selected from a multi-ethnic sample of the general US population; mean age was 61 years old, 56% women, 69% white, 13% current smokers. The median follow-up was 17 years, during which 649 participants died from respiratory causes and 560 died from lung cancer.
Researchers calculated the death rates from respiratory disease and lung cancer and then compared these rates between non-smokers, social smokers, and heavy smokers. Researchers took account of other factors that can influence death rates including age, sex, race, education attainment, and body weight.
The results showed that social smokers were 2.5 times as likely to die of respiratory disease and 8.6 times as likely to die of lung cancer vs non-smokers. Social smokers had around half the rate of death from respiratory diseases as heavy smokers, however, their rate of lung cancer death was two-thirds that of heavy smokers.
“You might think that if you only smoke a few cigarettes a day you are avoiding most of the risk. But our findings [sis] suggesting that social smoking is disproportionately harmful. Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely,” added Balte.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Digital Asthma Self Management Program Improves Symptom Control But Disparities in Benefit Are Clear
A smartphone-based asthma management program significantly enhanced symptom control, but may require engagement or cultural tailoring to expand the effect.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows
Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Validation Study of SANSA Home Sleep Apnea Test Published in Frontiers in Neurology, Huxley Medical Announces
Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.
Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma
EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.
Digital Asthma Self Management Program Improves Symptom Control But Disparities in Benefit Are Clear
A smartphone-based asthma management program significantly enhanced symptom control, but may require engagement or cultural tailoring to expand the effect.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows
Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Validation Study of SANSA Home Sleep Apnea Test Published in Frontiers in Neurology, Huxley Medical Announces
Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.
Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma
EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.